TaiMed Biologics (4147) — Cash Flow Reinvestment Rate

Latest as of December 2025: 2.64x

TaiMed Biologics (4147) has a Cash Flow Reinvestment Rate of 2.64x as of December 2025, reinvesting NT$68.58 Million (capex NT$16.75 Million plus investments NT$51.83 Million) from operating cash flow of NT$25.95 Million. Explore TaiMed Biologics capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

2.64x

(Capex + Investments) / Operating CF

Total Reinvested

NT$68.58 Million

Capex + Investments

Operating Cash Flow

NT$25.95 Million

TWD

Capital Expenditures

NT$16.75 Million

TWD

TaiMed Biologics Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for TaiMed Biologics across 1 annual periods. Also explore TaiMed Biologics balance sheet assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for TaiMed Biologics (2025–2025)

Year-by-year capital reinvestment analysis for TaiMed Biologics. For live market cap and broader valuation context, see TaiMed Biologics market capitalisation.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2025	1.04x	NT$199.46 Million	NT$191.14 Million	NT$22.77 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow